Targeted TREM2 inhibition exhibited remarkable anti-GBM therapeutic effect through promoting the infiltration of Th1 cells and CD8+T cells, reducing the infiltration of Th2 cells and Treg cells, repolarizing macrophages to M1-type, and decreasing the secretion of pro-tumor and immunosuppressive cytokines. The gene discussed is CD8A; the disease is glioblastoma.